Related Experiment Video
Updated: Jul 15, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen-independent prostate cancer
1ZNA Campus Middelheim, Antwerp, Belgium.
Summary
Androgen-independent prostate cancer (AIPC) progresses after hormone therapy. Standard AIPC treatment combines chemotherapy with continued castration, while new targeted drugs and vaccines are under investigation.
Area of Science:
- Oncology
- Urology
Background:
- Androgen-independent prostate cancer (AIPC) is defined as prostate cancer progression despite androgen-ablation therapy.
- AIPC typically emerges after a median of 18 months of hormone deprivation.
- Patients with AIPC have a median survival of 10-20 months, with prognosis predictable via nomograms.
Purpose of the Study:
- To outline the characteristics and current treatment landscape of androgen-independent prostate cancer (AIPC).
- To discuss established and emerging therapeutic strategies for managing advanced prostate cancer.
Main Methods:
- Review of current literature on androgen-independent prostate cancer (AIPC).
- Analysis of standard treatment protocols and emerging therapies.
Main Results:
- Standard treatment for AIPC involves continued castration with gonadotropin-releasing hormone (LHRH) agonists and docetaxel-based chemotherapy.
- Palliative care options include hormonal therapy, chemotherapy, radioisotopes, radiotherapy, and bisphosphonates.
- Novel targeted drugs and vaccination strategies are being evaluated for AIPC treatment.
Conclusions:
- Androgen-independent prostate cancer (AIPC) presents a significant clinical challenge with limited survival.
- Current management relies on combination chemotherapy and continued androgen deprivation.
- Ongoing research into targeted therapies and vaccines offers future hope for improved AIPC outcomes.
